1921
Volume 75, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

The chemosusceptibility and genetic polymorphism of populations from 48 patients hospitalized for malaria at the Hospital Principal in Dakar, Senegal were investigated during the 2002 malaria transmission season. Sixty-two percent of the isolates collected were from patients with severe malaria and 38% were from patients with mild malaria. activities of chloroquine, quinine, cycloguanil, atovaquone, mefloquine, halofantrine, and artesunate were evaluated. The prevalence of mutations in the dihydrofolate reductase () and dihyropteroate synthetase () genes and the chloroquine resistance transporter () gene associated with cycloguanil, pyrimethamine, sulfadoxine, and chloroquine resistance were estimated. The genetic polymorphism of the parasite populations was evaluated by analysis of the highly polymorphic regions of merozoite surface protein 1 () block 2 and Seventy percent of the isolates were assessed by an assay. Fifty-two percent of the isolates were chloroquine resistant, 45% were cycloguanil resistant, and 24% were atovaquone resistant. Four percent had low susceptibility to quinine. The and mutations were associated with chloroquine- and antimetabolic drug-resistant isolates, respectively. Approximately 70% of the isolates contained two or more clones. Genetic diversity of was high. The prevalence of allelic family K1 of was 68%. Isolates of were highly resistant to chloroquine, cycloguanil and atovaquone. The transmission rate of malaria in Dakar is low but a high degree of genetic polymorphism can increase severe malaria, as shown by persons coming to Dakar from areas highly endemic for malaria. Areas with urban malaria should use vector control measures and efficient chemoprophylaxis for non-immune populations.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2006.75.146
2006-07-01
2017-11-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/75/1/0750146.html?itemId=/content/journals/10.4269/ajtmh.2006.75.146&mimeType=html&fmt=ahah

References

  1. Badiaga S, Brouqui P, Carpentier JP, Hovette P, Duigou F, Manelli JC, Martin C, Delmont J, 2005. Severe imported malaria: clinical presentation at time of hospital admission and outcome in 42 cases diagnosed from 1996 to 2002. J Emerg Med 29 : 375–382.
  2. Leclerc MC, Durand P, de Meeus T, Robert V, Renaud F, 2002. Genetic diversity and population structure of Plasmodium falciparum isolates from Dakar, Senegal, investigated from microsatellite and antigen determinant loci. Microbes Infect 4 : 685–692.
  3. Badiker HA, Walliker D, 1997. Current views on the population structure of Plasmodium falciparum: implications for control. Parasitol Today 13 : 262–266.
  4. Robert F, Ntoumi F, Angel G, Candito D, Rogier C, Fandeur T, Sarthou JL, Mercereau-Puijalon O, 1996. Extensive genetic diversity of Plasmodium falciparum isolates collected from patients with severe malaria in Dakar, Senegal. Trans R Soc Trop Med Hyg 90 : 704–711.
  5. Schleiermacher D, Rogier C, Spiegel A, Tall A, Trape JF, Mercereau-Puijalon O, 2001. Increased multiplicity of Plasmodium falciparum infections and skewed distribution of individual msp1 and msp2 alleles during pregnancy in Ndiop, a Senegalese village with seasonal, mesoendemic malaria. Am J Trop Med Hyg 64 : 303–309.
  6. Trape JF, Lefebvre-Zante E, Legros F, Ndiaye G, Bouganali H, Druilhe P, Salem G, 1992. Vector density gradients and the epidemiology of urban malaria in Dakar, Senegal. Am J Trop Med Hyg 47 : 181–189.
  7. Parzy D, Doerig C, Pradines B, Rico A, Fusai T, Doury JC, 1997. Proguanil resistance in Plasmodium falciparum African isolates: assessment by mutation-specific polymerase chain reaction and in vitro susceptibility testing. Am J Trop Med Hyg 57 : 646–650.
  8. Wang P, Lee CS, Bayoumi R, Djimde A, Doumbo O, Swedberg G, Dao LD, Mshinda H, Tanner M, Watkins WM, Sims PF, Hyde JE, 1997. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol 89 : 161–177.
  9. Millet J, Alibert S, Torrentino-Madamet M, Rogier C, Santelli-Rouvier C, Bigot P, Mosnier J, Baret E, Barbe J, Parzy D, Pradines B, 2004. Polymorphism in Plasmodium falciparum drug transporter proteins and reversal of in vitro chloroquine resistance by a 9,10-dihydroethanoanthracene derivative. Antimicrob Agents Chemother 48 : 4869–4872.
  10. Zwetyenga J, Rogier C, Tall A, Fontenille D, Snounou G, Trape JF, Mercereau-Puijalon O, 1998. No influence of age on infection complexity and allelic distribution in Plasmodium falciparum infections in Ndiop, a Senegalese village with seasonal, mesoendemic malaria. Am J Trop Med Hyg 59 : 726–735.
  11. World Health Organization, 2000. Severe falciparum malaria. Trans R Soc Trop Med Hyg 94 (Suppl 1): 1–90.
  12. Gay F, Bustos D, Traore B, Jardinel C, Southammavong M, Ciceron L, Danis MM, 1997. In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: comparison between African and Asian strains. Am J Trop Med Hyg 56 : 315–317.
  13. Molez JF, Robert V, Trape JF, 1996. Chloroquine resistant strains of Plasmodium falciparum in the Anopheles vector and use of antimalarials. Dakar Med (Special) : 7–9.
  14. Hatin I, Trape JF, Legros F, Bauchet J, Le Bras J, 1992. Susceptibility of Plasmodium falciparum strains to mefloquine in an urban area in Senegal. Bull World Health Organ 70 : 363–367.
  15. Sokhna CS, Molez JF, Ndiaye P, Sane B, Trape JF, 1997. In vivo chemosensitivity tests of Plasmodium falciparum to chloroquine in Senegal: the development of resistance and the assessment of therapeutic efficacy. Bull Soc Pathol Exot 90 : 83–89.
  16. Pradines B, Tall A, Rogier C, Spiegel A, Mosnier J, Marrama L, Fusai T, Millet P, Panconi E, Trape JF, Parzy D, 2002. In vitro activities of ferrochloroquine against 55 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Trop Med Int Health 7 : 265–270.
  17. Sarr O, Myrick A, Daily J, Diop BM, Dieng T, Ndir O, Sow PS, Mboup S, Wirth DF, 2005. Prevalence of Plasmodium falciparum Pfcrt polymorphisms and in vitro chloroquine sensitivity in Senegal. Parasitol Res 97 : 136–140.
  18. de Monbrison F, Raynaud D, Latour-Fondanaiche C, Staal A, Favre S, Kaiser K, Peyron F, Picot S, 2003. Real-time PCR for chloroquine sensitivity assay and for pfmdr1-Pfcrt single nucleotide polymorphisms in Plasmodium falciparum. J Microbiol Methods 54 : 391–401.
  19. Ringwald P, Sukwa T, Basco LK, Bloland P, Mendis K, 2002. Monitoring of drug-resistant malaria in Africa. Lancet 360 : 875–876.
  20. Gari-Toussaint M, Pradines B, Mondain V, Keundjian A, Dellamonica P, Le Fichoux Y, 2002. Senegal and malaria. True prophylactic failure of mefloquine. Presse Med 31 : 1136.
  21. Pradines B, Rogier C, Fusai T, Tall A, Trape JF, Doury JC, 1996. In vitro sensitivity of 85 Plasmodium falciparum isolates in the Fatick region, Senegal. Med Trop (Mars) 56 : 141–145.
  22. Basco LK, Tahar R, Keundjian A, Ringwald P, 2000. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. J Infect Dis 182 : 624–628.
  23. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185 : 380–388.
  24. Le Bras J, Pradines B, Durand R, Parzy D, 2005. La prescription de l’association chloroquine-proguanil (Savarine) est-elle tou-jours justifiée pour la prévention du paludisme en zone 2? Rev Prat 55 : 856–857.
  25. Anonymous, 2005. Recommandations sanitaires pour les voyageurs 2005. BEH 24–25 : 118–125.
  26. Hudson AT, 1993. Atovaquone—a novel broad-spectrum anti-infective drug. Parasitol Today 9 : 66–68.
  27. Gassis S, Rathod PK, 1996. Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoro-orotate and atovaquone suppresses in vitro resistance. Antimicrob Agents Chemother 40 : 914–919.
  28. Rathod PK, McErlean T, Lee PC, 1997. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 94 : 9389–9393.
  29. Basco LK, 2003. Molecular epidemiology of malaria in Cameroon. XVII. Baseline monitoring of atovaquone-resistant Plasmodium falciparum by in vitro drug assays and cytochrome b gene sequence analysis. Am J Trop Med Hyg 69 : 179–183.
  30. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q, 2000. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 44 : 2100–2108.
  31. Farnert A, Lindberg J, Gil P, Swedberg G, Berqvist Y, Thapar MM, Lindegardh N, Berezcky S, Bjorkman A, 2003. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ 326 : 628–629.
  32. Thapar MM, Gil JP, Bjorkman A, 2005. In vitro recrudescence of Plasmodium falciparum parasites suppressed to dormant state by atovaquone alone and in combination with proguanil. Trans R Soc Trop Med Hyg 99 : 62–70.
  33. Ntoumi F, Contamin H, Rogier C, Bonnefoy S, Trape JF, Mercereau-Puijalon O, 1995. Age-dependent carriage of multiple Plasmodium falciparum merozoite surface antigen-2 alleles in asymptomatic malaria infections. Am J Trop Med Hyg 52 : 81–88.
  34. Konate L, Zwetyenga J, Rogier C, Bischoff E, Fontenille D, Tall A, Spiegel A, Trape JF, Mercereau-Puijalon O, 1999. Variation of Plasmodium falciparum msp1 block 2 and msp2 allele prevalence and of infection complexity in two neighbouring Senegalese villages with different transmission conditions. Trans R Soc Trop Med Hyg 93 : 21–28.
  35. Conway DJ, Greenwood BM, McBride JS, 1991. The epidemiology of multiple-clone Plasmodium falciparum infections in Gambian patients. Parasitology 103 : 1–6.
  36. Aubouy A, Migot-Nabias F, Deloron P, 2003. Polymorphism in two merozoite surface proteins of Plasmodium falciparum isolates from Gabon. Malar J 2 : 12.
  37. Baudon D, Louis FJ, Martet G, 1996. In Africa, urban malaria is the malaria of tomorrow. Med Trop (Mars) 56 : 323–325.
  38. Le Bras J, Ringwald P, 1990. Plasmodium falciparum chemore-sistance. The situation in Africa in 1989. Med Trop (Mars) 50 : 161–162.
  39. Basco LK, Le Bras J, 1994. In vitro susceptibility of Cambodian isolates of Plasmodium falciparum to halofantrine, pyronaridine and artemisinin derivatives. Ann Trop Med Parasitol 88 : 137–144.
  40. Basco LK, Le Bras J, 1992. In vitro activity of halofantrine and its relationship to other standard antimalarial drugs against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 47 : 521–527.
  41. Basco LK, Ramiliarisoa O, Le Bras J, 1994. In vitro activity of pyrimethamine, cycloguanil, and other antimalarial drugs against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 50 : 193–199.
  42. Pradines B, Rogier C, Fusai T, Tall A, Trape JF, Doury JC, 1998. In vitro activity of artemether against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial drugs. Am J Trop Med Hyg 58 : 354–357.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2006.75.146
Loading
/content/journals/10.4269/ajtmh.2006.75.146
Loading

Data & Media loading...

  • Received : 20 Jul 2005
  • Accepted : 21 Feb 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error